Cabaletta Bio
Clinical-stage biotechnology company developing engineered T cell therapies for patients with autoimmune diseases, using its Chimeric AutoAntibody Receptor (CAAR) T cell platform.
Website
https://www.cabalettabio.comLocation
Philadelphia, Pennsylvania, USA
Founded
2017
Categories
biotech, cell-therapy, car-t, autoimmune-disease, immunology
Notes
Cabaletta Bio (NASDAQ: CABA) is a clinical-stage biotechnology company pioneering the development of engineered T cell therapies for autoimmune diseases. The company's CAAR (Chimeric AutoAntibody Receptor) T cell platform is designed to selectively target and eliminate B cells that produce disease-causing autoantibodies.
Founded in 2017, Cabaletta Bio is developing treatments for conditions such as mucosal pemphigus vulgaris (mPV) and other autoimmune diseases. The company went public in 2020 and is headquartered in Philadelphia, Pennsylvania.
Team
- Steven Nichtberger, M.D. - Co-founder, President & Chief Executive Officer
- LinkedIn: linkedin.com/in/stevennichtberger
- Aimee Payne, M.D., Ph.D. - Co-founder & Scientific Founder
- Michael Milone, M.D., Ph.D. - Co-founder & Scientific Founder
- Gwen Binder - Chief Financial Officer
Additional Research Findings
- NASDAQ: CABA (publicly traded)
- Founded in 2017, IPO in 2020
- CAAR T cell platform for autoimmune diseases
- Lead programs target mucosal pemphigus vulgaris and other autoimmune conditions
- Scientific founders from University of Pennsylvania
- Backed by Bain Capital Life Sciences among other investors
- Headquarters in Philadelphia, PA
- Focus on B cell-mediated autoimmune diseases